Innate Pharma (IPHYF) Enterprise Value (2017 - 2025)
Innate Pharma's Enterprise Value history spans 9 years, with the latest figure at -$39.9 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 53.73% year-over-year to -$39.9 million; the TTM value through Dec 2025 reached -$39.9 million, up 53.73%, while the annual FY2025 figure was -$39.9 million, 54.31% up from the prior year.
- Enterprise Value reached -$39.9 million in Q4 2025 per IPHYF's latest filing, up from -$86.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$39.9 million in Q4 2025 to a low of -$137.1 million in Q4 2021.
- Average Enterprise Value over 5 years is -$93.3 million, with a median of -$99.5 million recorded in 2023.
- Peak YoY movement for Enterprise Value: rose 3.92% in 2023, then soared 53.73% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$137.1 million in 2021, then rose by 24.47% to -$103.5 million in 2022, then increased by 3.92% to -$99.5 million in 2023, then grew by 13.24% to -$86.3 million in 2024, then skyrocketed by 53.73% to -$39.9 million in 2025.
- Per Business Quant, the three most recent readings for IPHYF's Enterprise Value are -$39.9 million (Q4 2025), -$86.3 million (Q4 2024), and -$99.5 million (Q4 2023).